FOI 25-0076 LD – Securing Supply Of Prep

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

**Document type:** Government press release and email correspondence regarding PBS listing and supply management. **Health intervention:** Pre-exposure prophylaxis (PrEP)—specifically tenofovir with emtricitabine for HIV prevention. **Substance disclosed:** In October 2024, the Department of Health announced temporary PBS listing of an alternative overseas-registered brand (Laurus Labs, USA-registered) to address a supply shortage of PrEP. The measure was intended to maintain subsidised access for approximately 27,000 eligible patients during the shortage period. The disclosure shows the department coordinated messaging with external health organisations (Australian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Health Equity Matters) before public announcement. A stakeholder raised a technical clarification about the eligibility statement describing PrEP recipients as "with or at risk of contracting HIV," noting PrEP is indicated only for people without